Combined Targeting of CSF-1R and IDO Alters the Fibrotic and Immunosuppressive Environment in Pancreatic Ductal Adenocarcinoma

Overview

This study investigates the effects of dual targeting of CSF-1R and IDO in pancreatic ductal adenocarcinoma (PDAC) models. The findings indicate that this combination therapy significantly reduces tumor burden in highly fibrotic tumors.

Background

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a poor prognosis, characterized by extensive fibrosis and an immunosuppressive tumor microenvironment (TME). The fibrotic stroma and tumor-associated macrophages (TAMs) contribute to immune evasion and limit the efficacy of existing therapies. Understanding the interactions within the TME is crucial for developing effective treatment strategies.

Data Highlights

No numerical data or trial results were provided in the source material.

Key Findings

• Highly fibrotic KPC4662.5 tumors exhibited elevated levels of Arg1, α-SMA, TGF-β1, and CSF-1R compared to Pan02 tumors.
• Dual targeting of CSF-1R and IDO significantly reduced tumor burden in KPC4662.5 tumors.
• No combination advantage was observed in CSF1RLow tumors.
• The combination therapy altered the intratumoral immune cell composition by decreasing PMN-MDSCs and increasing effector T cell subsets.
• CSF-1R expression and tumor fibrosis may serve as potential biomarkers for response to combined therapy.

Clinical Implications

Understanding the context-dependent nature of therapeutic responses is essential for optimizing treatment approaches.

Conclusion

The findings indicate that targeting both CSF-1R and IDO may be a strategy in treating fibrotic PDAC, warranting further investigation.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- IL-6 as a central driver of immune evasion in PDAC: from IDO-mediated tolerance to multi-pathway immunosuppression
2. Journal of Gastroenterology, 2026 -- Mucosal-associated invariant T cells promote PDAC progression via TL1A–CSF-1 axis
3. Journal of Gastroenterology, 2026 -- Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma
4. ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer - PMC
5. Journal of Gastroenterology — Epigenetic Modulation of Pancreatic Adenocarcinoma in the Context of Cancer Immunotherapy
6. The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities | Nature Reviews Clinical Oncology
7. ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer - PMC
8. EudraCT Number 2018-000339-28 - Clinical trial results - EU Clinical Trials Register